LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based ...

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...

Like the Lumipulse test, this is a simple blood draw that can identify phosphorylated tau proteins, which correlates with the presence of amyloid plaques and therefore the potential for Alzheimer’s.

Lumipulse blood test: A significant milestone for Alzheimer’s disease Alzheimer’s disease is a progressive brain disorder and the most common cause of dementia. It leads to memory loss, confusion, ...

A new blood test is being called a game changer for helping diagnose Alzheimer’s, and UNLV helped contribute research to it.

In terms of quality of life, someone 75 years old, retired with significant memory problems, can still have friends and, “a good life,” with early detection and treatment.